Literature DB >> 19496184

Human herpesvirus 6 infections after liver transplantation.

Rima Camille Abdel Massih1, Raymund R Razonable.   

Abstract

Human herpesvirus 6 (HHV-6) infections occur in > 95% of humans. Primary infection, which occurs in early childhood as an asymptomatic illness or manifested clinically as roseola infantum, leads to a state of subclinical viral persistence and latency. Reactivation of latent HHV-6 is common after liver transplantation, possibly induced and facilitated by allograft rejection and immunosuppressive therapy. Since the vast majority of humans harbor the virus in a latent state, HHV-6 infections after liver transplantation are believed to be mostly due to endogenous reactivation or superinfection (reactivation in the transplanted organ). In a minority of cases, however, primary HHV-6 infection may occur when an HHV-6 negative individual receives a liver allograft from an HHV-6 positive donor. The vast majority of documented HHV-6 infections after liver transplantation are asymptomatic. In a minority of cases, HHV-6 has been implicated as a cause of febrile illness with rash and myelosuppression, hepatitis, pneumonitis, and encephalitis after liver transplantation. In addition, HHV-6 has been associated with a variety of indirect effects such as allograft rejection, and increased predisposition and severity of other infections including cytomegalovirus (CMV), hepatitis C virus, and opportunistic fungi. Because of the uncommon nature of the clinical illnesses directly attributed to HHV-6, there is currently no recommended HHV-6-specific approach to prevention. However, ganciclovir and valganciclovir, which are primarily intended for the prevention of CMV disease, are also active against HHV-6 and may prevent its reactivation after transplantation. The treatment of established HHV-6 disease is usually with intravenous ganciclovir, cidofovir, or foscarnet, complemented by reduction in the degree of immunosuppression. This article reviews the current advances in the pathogenesis, clinical diagnosis, and therapeutic modalities against HHV6 in the setting of liver transplantation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19496184      PMCID: PMC2691485          DOI: 10.3748/wjg.15.2561

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  94 in total

Review 1.  Membrane cofactor protein (MCP or CD46): newest member of the regulators of complement activation gene cluster.

Authors:  M K Liszewski; T W Post; J P Atkinson
Journal:  Annu Rev Immunol       Date:  1991       Impact factor: 28.527

2.  Susceptibility of human herpesvirus 6 to antivirals in vitro.

Authors:  W H Burns; G R Sandford
Journal:  J Infect Dis       Date:  1990-09       Impact factor: 5.226

3.  Infection of natural killer cells by human herpesvirus 6.

Authors:  P Lusso; M S Malnati; A Garzino-Demo; R W Crowley; E O Long; R C Gallo
Journal:  Nature       Date:  1993-04-01       Impact factor: 49.962

4.  Human herpesvirus-6 infection in children. A prospective study of complications and reactivation.

Authors:  C B Hall; C E Long; K C Schnabel; M T Caserta; K M McIntyre; M A Costanzo; A Knott; S Dewhurst; R A Insel; L G Epstein
Journal:  N Engl J Med       Date:  1994-08-18       Impact factor: 91.245

5.  Human herpesvirus 6 induces interleukin-1 beta and tumor necrosis factor alpha, but not interleukin-6, in peripheral blood mononuclear cell cultures.

Authors:  L Flamand; J Gosselin; M D'Addario; J Hiscott; D V Ablashi; R C Gallo; J Menezes
Journal:  J Virol       Date:  1991-09       Impact factor: 5.103

6.  Human herpesvirus-6 infection in bone marrow transplantation.

Authors:  T Yoshikawa; S Suga; Y Asano; T Nakashima; T Yazaki; R Sobue; M Hirano; M Fukuda; S Kojima; T Matsuyama
Journal:  Blood       Date:  1991-09-01       Impact factor: 22.113

7.  Human herpesvirus 6 (HHV-6) isolation from bone marrow: HHV-6-associated bone marrow suppression in bone marrow transplant patients.

Authors:  D R Carrigan; K K Knox
Journal:  Blood       Date:  1994-11-15       Impact factor: 22.113

8.  Human herpesvirus 6 (HHV-6) variant B accounts for the majority of symptomatic primary HHV-6 infections in a population of U.S. infants.

Authors:  S Dewhurst; K McIntyre; K Schnabel; C B Hall
Journal:  J Clin Microbiol       Date:  1993-02       Impact factor: 5.948

9.  Primary human herpesvirus 6 infection in young children.

Authors:  P Pruksananonda; C B Hall; R A Insel; K McIntyre; P E Pellett; C E Long; K C Schnabel; P H Pincus; F R Stamey; T R Dambaugh
Journal:  N Engl J Med       Date:  1992-05-28       Impact factor: 91.245

10.  Frequent isolation of HHV-6 from saliva and high seroprevalence of the virus in the population.

Authors:  J A Levy; F Ferro; D Greenspan; E T Lennette
Journal:  Lancet       Date:  1990-05-05       Impact factor: 79.321

View more
  18 in total

1.  Quantitative HHV-6B antigenemia test for the monitoring of transplant patients.

Authors:  R Loginov; T Karlsson; K Höckerstedt; D Ablashi; I Lautenschlager
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-04-21       Impact factor: 3.267

Review 2.  Neurologic complications after liver transplantation.

Authors:  Saša A Zivković
Journal:  World J Hepatol       Date:  2013-08-27

3.  Ganciclovir-resistant human herpesvirus-6 encephalitis in a liver transplant patient: a case report.

Authors:  Kelly Baldwin
Journal:  J Neurovirol       Date:  2011-02-02       Impact factor: 2.643

4.  Viral and paraneoplastic encephalitis in a patient with liver transplant with unilateral temporoparietal lobe abnormalities: a diagnostic challenge.

Authors:  Christopher K Cheng; Keith A Siller
Journal:  BMJ Case Rep       Date:  2013-05-31

5.  Detection frequency of human herpesviruses-6A, -6B, and -7 genomic sequences in central nervous system DNA samples from post-mortem individuals with unspecified encephalopathy.

Authors:  Svetlana Chapenko; Silvija Roga; Sandra Skuja; Santa Rasa; Maksims Cistjakovs; Simons Svirskis; Zane Zaserska; Valerija Groma; Modra Murovska
Journal:  J Neurovirol       Date:  2016-01-04       Impact factor: 2.643

Review 6.  Monitoring and managing viral infections in pediatric renal transplant recipients.

Authors:  Patrizia Comoli; Fabrizio Ginevri
Journal:  Pediatr Nephrol       Date:  2011-02-26       Impact factor: 3.714

7.  Impact of human herpes virus 6 in liver transplantation.

Authors:  Raymund R Razonable; Irmeli Lautenschlager
Journal:  World J Hepatol       Date:  2010-09-27

8.  Virus reactivation: a panoramic view in human infections.

Authors:  Christopher M Traylen; Hersh R Patel; Wylder Fondaw; Sheran Mahatme; John F Williams; Lia R Walker; Ossie F Dyson; Sergio Arce; Shaw M Akula
Journal:  Future Virol       Date:  2011-04       Impact factor: 1.831

9.  Infectious Complications After Liver Transplantation.

Authors:  Maria Del Pilar Hernandez; Paul Martin; Jacques Simkins
Journal:  Gastroenterol Hepatol (N Y)       Date:  2015-11

10.  Monitoring of active human herpes virus 6 infection in Iranian patients with different subtypes of multiple sclerosis.

Authors:  Nourollah Ramroodi; Nima Sanadgol; Zohre Ganjali; Abbas Ali Niazi; Vida Sarabandi; Ali Moghtaderi
Journal:  J Pathog       Date:  2013-01-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.